Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I under synthetic cannabinoid regulation. This reflects concerns about its high abuse potential and health risks. Clinicians should be aware of the challenges in detecting these…
DEA Regulation on Synthetic Ketamine Analog 2-Fluorodeschloroketamine
The DEA synthetic ketamine analog regulation has led to the temporary placement of 2-fluorodeschloroketamine in Schedule I. This action addresses emerging risks from unregulated synthetic ketamine analogs. Clinicians should be aware of the DEA synthetic…
Schedules of Controlled Substances: DEA Synthetic Cannabinoids Schedule I Placement 2026
The DEA synthetic cannabinoids schedule I placement 2026 marks a critical regulatory update for controlled substances. This action targets compounds like CUMYL-PEGACLONE due to high abuse potential. Clinicians must understand the clinical relevance of…
DEA Control of Synthetic Ketamine Analogs: 2-Fluorodeschloroketamine Scheduling
The DEA synthetic ketamine analog control includes the temporary Schedule I placement of 2-fluorodeschloroketamine (2-FDCK). This action addresses emerging synthetic drugs posing clinical and regulatory challenges. Clinicians should stay informed about…
Schedules of Controlled Substances: DEA Synthetic Cannabinoids Schedule I Placement
The DEA synthetic cannabinoids schedule I placement 2026 update designates CUMYL-PEGACLONE as a Schedule I substance. This reflects the ongoing regulatory efforts to control potent synthetic cannabinoids. Clinicians should be aware of the unique clinical…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA scheduling updates include the temporary placement of 2-Fluorodeschloroketamine in Schedule I due to its abuse potential. This regulatory action highlights challenges in controlling novel synthetic substances. Clinicians should stay informed…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has designated synthetic cannabinoids schedule I designation for CUMYL-PEGACLONE due to its high abuse potential and no accepted medical use. This scheduling reflects ongoing regulatory efforts to control novel synthetic cannabinoids. Clinicians…